GANX - CIK 0001819411
The table below shows Gain Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$18.47M | -$18.87M | -$18.87M | -$14.69M | -$12.37M | -$3.24M |
| Capital expenditure | - | - | - | - | $94.21K | $20.83K |
| Investing cash flow | - | $4.98M | $10.22M | -$14.77M | -$94.21K | -$20.83K |
| Dividends paid | - | - | - | - | - |
Gain Therapeutics, Inc. reported operating cash flow of -$18.47M for fiscal year 2025. That is up 2.2% from -$18.87M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$3.24M (FY 2020) to -$18.47M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $28.45M | $13.01M | $12.64M | -$78.77K | $41.77M | $10.49M |